Evidence map›Paper›PMID 29963263›Full record

ArticleOncotarget2018

Prognostic stratification of adult primary glioblastoma multiforme patients based on their tumor gene amplification profiles.

María González-Tablas, Inês Crespo, Ana Luísa Vital, Álvaro Otero, Ana Belén Nieto, Pablo Sousa, María Carmen Patino-Alonso, Luis Antonio Corchete, Hermínio Tão, Olinda Rebelo and 7 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. HeterogeneousCancers · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 3 countries.

María González-TablasCentre for Cancer Research (CIC IBMCC-CSIC/USAL), Department of Medicine, CIBERONC, University of Salamanca, Salamanca, Spain.
Inês CrespoCentre for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
Ana Luísa VitalCentre for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
Álvaro OteroServicio de Neurocirugía, Hospital Universitario e Instituto Biosanitario de Salamanca (IBSAL), Salamanca, Spain.
Ana Belén NietoDepartment of Statistics, University of Salamanca, Salamanca, Spain.
Pablo SousaServicio de Neurocirugía, Hospital Universitario e Instituto Biosanitario de Salamanca (IBSAL), Salamanca, Spain.
María Carmen Patino-AlonsoDepartment of Statistics, University of Salamanca, Salamanca, Spain.
Luis Antonio CorcheteDepartamento de Hematología, Hospital Universitario, IBSAL, IBMCC (USAL-CSIC), Salamanca, Spain.
Hermínio TãoNeurosurgery Service, University Hospital of Coimbra, Coimbra, Portugal.
Olinda RebeloNeuropathology Laboratory, Neurology Service, University Hospital of Coimbra, Coimbra, Portugal.
Marcos BarbosaNeurosurgery Service, University Hospital of Coimbra, Coimbra, Portugal.
Maria Rosário AlmeidaCentre for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
Ana Filipa GuedesCentre for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
María Celeste LopesCentre for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
Pim J FrenchDepartment of Neurology, Erasmus MC, Rotterdam, The Netherlands.
Alberto OrfaoCentre for Cancer Research (CIC IBMCC-CSIC/USAL), Department of Medicine, CIBERONC, University of Salamanca, Salamanca, Spain.
María Dolores TaberneroCentre for Cancer Research (CIC IBMCC-CSIC/USAL), Department of Medicine, CIBERONC, University of Salamanca, Salamanca, Spain.
University of Coimbra · PTInstituto de Investigación Biomédica de Salamanca · ESCentro de Investigación del Cáncer · ESUniversidad de Salamanca · ESCentro de Investigación Biomédica en Red de Cáncer · ESErasmus MC · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several classification systems have been proposed to address genomic heterogeneity of glioblastoma multiforme, but they either showed limited prognostic value and/or are difficult to implement in routine diagnostics. Here we propose a prognostic stratification model for these primary tumors based on tumor gene amplification profiles, that might be easily implemented in routine diagnostics, and potentially improve the patients management. Gene amplification profiles were prospectively evaluated in 80 primary glioblastoma multiforme tumors using single-nucleotide polymorphism arrays and the results obtained validated in publicly available data from 267/347 cases. Gene amplification was detected in 45% of patients, and chromosome 7p11.2 including the

Indexed as

classificationgene amplificationglioblastomasubtypessurvival

Identifiers

PMID29963263
PMCPMC6021328
OpenAlexW2807845858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.